Weight Loss & Metabolic

A GLP-1 receptor agonist widely studied for metabolic regulation and body weight management.

A dual GIP/GLP-1 receptor agonist representing the next generation of incretin-based therapies.

A novel triple agonist targeting GIP, GLP-1, and glucagon receptors for unprecedented metabolic effects.

A modified fragment of human growth hormone studied for fat metabolism without growth-promoting effects.

A once-daily GLP-1 receptor agonist approved for diabetes and weight management.

A small molecule NNMT inhibitor studied for metabolic regulation and fat cell metabolism.

A long-acting amylin analog for appetite regulation and glycemic control.

A glucagon/GLP-1 dual agonist developed for obesity and metabolic disorders.

A glucagon/GLP-1 dual agonist in development for MASH and obesity.

The fat-burning fragment of human growth hormone without anabolic effects.

An AMP-kinase activator that mimics exercise effects on metabolism and endurance.

A long-acting GLP-1 receptor agonist for type 2 diabetes and weight management.

A peptide that targets and destroys fat tissue blood vessels, causing rapid fat loss.

An amino acid derivative essential for fatty acid transport and energy metabolism.

A lipotropic injection combining methionine, inositol, and choline for fat metabolism.

A lipolytic injection containing bromelain, riboflavin, and lecithin for fat dissolution.

A combination of cagrilintide and semaglutide for enhanced weight loss effects.

A combination of triple agonist retatrutide with amylin analog cagrilintide for maximum weight loss.

A combination of triple and dual agonists for aggressive weight management.

Enhanced lipotropic injection combining MIC with vitamin B12 for energy and fat metabolism.

A metabolic support formulation designed to complement ketogenic and low-carb protocols.